Medical beauty industry practitioner Xiao Xue told Fujian financial reporter, Runbayan acquisition price in about five hundred yuan, Ewan in about one thousand yuan, Joyalden in about three thousand five to four thousand yuan." On the one hand, imported products are more expensive due to taxes and fees. For example, if Joe Arden is taken from a Korean hospital, it only costs eight hundred dollars. On the other hand, imported hyaluronic acid does offer better contouring, longer maintenance and fewer allergic components. Of course, some high-priced products also have added value such as outer packaging and hype.
Benefiting from the "value economy", the hyaluronic acid sunrise industry is characterized by high gross profit margins and many application scenarios, and its potential is being unleashed. CITIC Securities research report predicts that by 2020, China's hyaluronic acid cosmetic needle market demand will grow to 20 million to 30 million milliliters, becoming a 100 billion yuan market. In the hyaluronic acid business, upstream manufacturers can earn gross margins of more than 70%, while downstream hospitals and medical institutions depend on the specific pricing and positioning of hyaluronic acid products.
"The beauty industry is very lucrative, from beauty parlors to medical cosmetology, all of which rely on selling technology to make money. In addition, hyaluronic acid is a micro-modeling project, you can immediately become beautiful when you get it on your lunch break, so it is particularly popular and in high demand. In addition, if it is some informal medical institutions and U.S. institutions, personnel are not qualified, it will be more profitable.
Industry data show that items such as hyaluronic acid fillers ranked first in sales of non-surgical medical cosmetic items in China. Next, medical aesthetics will usher in a wave of rapid growth in China. In the short term, the business prospects of hyaluronic acid is still considerable, but because of its lower threshold, the market competition is bound to be more intense, coupled with the high cost of medicine and marketing in the United States, it may not become a long-term "cash cow".